-+ 0.00%
-+ 0.00%
-+ 0.00%

Lisata Therapeutics acquires Marea Therapeutics in pipeline pivot toward cardioendocrine drugs

PUBT·09/17/2026 13:27:17
Listen to the news
Lisata Therapeutics acquires Marea Therapeutics in pipeline pivot toward cardioendocrine drugs
  • Lisata Therapeutics acquired clinical-stage biotech Marea Therapeutics to pivot toward cardioendocrine drug development.
  • Deal paired with a private placement of Series C non-voting convertible preferred stock targeting gross proceeds of about $225 million.
  • Proceeds earmarked to advance MAR001/005 in severe hypertriglyceridemia through Phase 2b, with topline data expected in Q4 2027.
  • Funding also supports MAR002 in acromegaly entering Phase 2, with topline results also targeted for Q4 2027.
  • Company projected the financing will fund operations into 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609170926PRIMZONEFULLFEED9828959) on September 17, 2026, and is solely responsible for the information contained therein.